[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fetal-death\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fetal-death":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":43,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":5},"100345304","fetal-electrophysiologic-abnormalities-in-high-risk-pregnancies-associated-with-fetal-demise-100345304",false,"NCT03775954","Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise","Fetal Electrophysiologic Abnormalities in High-risk Pregnancies Associated With Fetal Demise","Inclusion Criteria:\n\n* Current pregnancy complicated by one of the five diagnostic categories\n\n  * prior unexplained Stillbirth at\u002Fafter 20 weeks gestation\n  * fetal major congenital heart defect\n  * fetal hydrops\n  * fetal gastroschisis\n  * monochorionic twin pregnancy\n* Subject must be 18 years of age or older\n* Subject must be English speaking and must be able to read and sign the consent form in English\n* Subject must be able to recline comfortably for 1-3 hours\n* Subject must be willing to complete all three procedures (fMCG, fMCG, nECG) as per protocol, unless medically unable\n* Subject must be willing to allow us to review her and her infants prenatal, deliver, and post-natal records to verify diagnosis, and clinical findings.\n\nExclusion Criteria:\n\n* Severe claustrophobia not reduced by taking breaks, or by having the light on, or by having someone in the room with them.\n* Active labor\n* Acute illness\n* Unable to recline comfortably with a pillow for more than 1-3 hours (assuming some breaks are provided)\n* Weight over 450 lbs\n* An electric stimulation device (TENS unit, pacemaker, or nerve stimulator) that could produce electric or magnetic noise.\n\n  * Note that the Tristan 624 Magnetometer does not pose a risk to the subject's device, (since fMCG does not produce any energy or magnetism), but stimulators themselves can cause interference for our recordings. Some devices may still qualify, and discussion with study nurse may be useful if subject has a pacemaker or similar device.\n\nThe subject will have a single 2-3 hour fetal magnetocardiogram at approximately 20 and 27 weeks GA, and again, if medical condition allows, between 30 and 37 weeks GA, then her infant will have an ECG between 0 and 4 weeks of age. Subjects will be paid a nominal fee for their participation each time, as well as transportation reimbursement if \\>25 miles. For subjects traveling a long distance, the ECG may be performed locally or at home.","FEMALE","18 Years",{"count":19,"type":20},30,"ESTIMATED","OBSERVATIONAL","Each year world-wide, 2.5 million fetuses die unexpectedly in the last half of pregnancy, 25,000 in the United States, making fetal demise ten-times more common than Sudden Infant Death Syndrome. This study will apply a novel type of non-invasive monitoring, called fetal magnetocardiography (fMCG) used thus far to successfully evaluate fetal arrhythmias, in order to discover potential hidden electrophysiologic abnormalities that could lead to fetal demise in five high-risk pregnancy conditions associated with fetal demise.",[24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42],"High Risk Pregnancy","Congenital Heart Disease","Fetal Hydrops","Twin Monochorionic Monoamniotic Placenta","Gastroschisis","Fetal Demise","Stillbirth","Fetal Arrhythmia","Long QT Syndrome","Intrauterine Fetal Death","Sudden Infant Death","Pregnancy Loss","Twin Twin Transfusion Syndrome","Birth Defect","Fetal Cardiac Anomaly","Fetal Cardiac Disorder","Fetal Death","Brugada Syndrome","Fetal Tachycardia",[44,30,45,46,47,24,48,49,50,51,52,53,54],"Fetal Magnetocardiography","Intrauterine Fetal Demise","Fetal Heart Rate Variability","Fetal Arrhythmias","Pregnancy","Fetal Anomaly","Fetal Echocardiography","Non-Stress Testing","New Technology","Birth Defects","Fetal Research","RECRUITING","2026-03-02",{"date":58,"type":59},"2026-03-04","ACTUAL",{"date":61,"type":59},"2018-07-01",{"date":63,"type":20},"2028-11-30",{"name":65,"class":66},"Medical College of Wisconsin","OTHER",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":16,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100336573","investigating-the-structured-use-of-ultrasound-scanning-for-fetal-growth-100336573","NCT03662178","Investigating the Structured Use of Ultrasound Scanning for Fetal Growth","Investigating the Structured Use of Ultrasound Scanning for Fetal Growth (Oxford Growth Restriction Identification Programme (OxGRIP)) on Risk Factors for and the Incidences of Adverse Maternal, Fetal and Neonatal Outcome","OxGRIP","Inclusion Criteria:\n\n• All pregnant women receiving antenatal care at the Oxford University Hospitals NHS Foundation Trust (OUHFT) from January 2013 to 31st December 2019 with no exclusion criteria\n\nExclusion Criteria:\n\n* Women who have opted out of research related to pregnancy in this pregnancy whilst receiving care by the OUHFT.\n* If intrapartum care takes place outside of the OUHFT.",true,"16 Years","60 Years",{"count":79,"type":20},56000,"Fetal growth restriction during pregnancy represents one of the biggest risk factors for stillbirth (Gardosi et al, 2013), with 'about one in three term, normally formed antepartum stillbirths are related to abnormalities of fetal growth' (MBRRACE, 2015).\n\nTherefore, antenatal detection of growth restricted babies is vital in order to be able to monitor and decide the appropriate delivery timing.\n\nHowever, antenatal detection of SGA babies has been poor, varying greatly across trusts in England in those that calculate their rates (NHS England, 2016). Most trusts do not calculate their detection rates and rates are therefore unknown. It is estimated that routine NHS care detects only 1 in 4 growth restricted babies (Smith, 2015).\n\nOxford University Hospitals NHS Foundation Trust, in partnership with the Oxford Academic Health Science Network (AHSN) has introduced a clinical care pathway (the Oxford Growth Restriction Pathway (OxGRIP)) designed to increase the rates of detection of these at risk babies. The pathway is intended to increase the identification of babies who are at risk of stillbirth, in order to try to prevent this outcome, whilst making best usage of resources, and restricting inequitable practice and unnecessary obstetric intervention.\n\nIt has been developed with reference to a body of research, however, the individual parts of care provided have not been put together in a pathway in this manner before. Therefore it is important to examine whether the pathway meets its goals of improving outcomes for babies in a 'real world' setting.\n\nThe principles of the pathway are\n\n1. A universal routine scan at 36 weeks gestation.\n2. Additional growth scans at 28 and 32 weeks gestation based on a simplified assessment of risk factors and universal uterine artery Doppler at 20 weeks gestation.\n3. Assessment of further parameters other than estimated fetal weight associated with adverse perinatal outcome (eg growth velocity, umbilical artery Doppler and CPR).\n\nThe clinical data routinely collected as a result of the introduction of the pathway offers a valuable and unique resource in identifying and analysing in the effects of the pathway on its intended outcomes and also in investigating and analysing other maternal, fetal and neonatal complications and outcomes, establishing normal \u002F reference ranges for ultrasound values.",[30,40,82,83,84,85,86],"Fetal Growth Retardation","Small for Gestational Age","Fetal Growth Restriction","Perinatal Death","Intrauterine Growth Restriction","2026-01-27",{"date":89,"type":59},"2026-01-29",{"date":91,"type":59},"2017-09-01",{"date":93,"type":20},"2029-09-30",{"name":95,"class":66},"Oxford University Hospitals NHS Trust",1]